You need Premium to read this article.
With a Premium subscription, you unlock all content on BioStock.
One-carbon Therapeutics doses first patient
Text:
Kim Liedholm | [email protected]
One-carbon Therapeutics has dosed the first patient in the Phase I/II clinical trial ODIN with the drug candidate TH9619. This marks the beginning of the clinical development of a new treatment targeting solid tumors with...